Try the modernized beta website. Learn more about the modernization effort.
Working… Menu
Trial record 1 of 1 for:    Intermittent Naltrexone Among Polysubstance Users (Project iN)
Previous Study | Return to List | Next Study

Intermittent Naltrexone Among Polysubstance Users (Project iN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01723384
Recruitment Status : Completed
First Posted : November 7, 2012
Results First Posted : February 12, 2019
Last Update Posted : April 23, 2019
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Glenn-Milo Santos, University of California, San Francisco

Brief Summary:
Naltrexone, a µ-opioid receptor antagonist, is a promising agent for methamphetamine-using and binge-drinking men who have sex with men (MSM). Naltrexone has shown efficacy in reducing relapse to amphetamines and is FDA-approved for alcohol dependence. Oral naltrexone is inexpensive and has few toxicities but the standard daily regimen for naltrexone is problematic as patients forget to take the medication. Given the challenges in daily dosing, alternate regimen schedules have been proposed to increase efficacy and expand the population that may benefit from this pharmacologic agent. One approach is intermittent targeted administration of naltrexone, whereby individuals take the medication as-needed in anticipation of substance use or during periods of craving. Administration of naltrexone prior to exposure to amphetamines significantly attenuates craving and targeted naltrexone has shown efficacy in reducing heavy alcohol use. However, there have been no studies assessing intermittent targeted dosing of naltrexone among methamphetamine-using and binge-drinking MSM. Polysubstance use patterns are common among MSM, and studies among those who abuse more than one substance are urgently needed. The aims of this study are to determine whether targeted dosing of naltrexone is feasible, tolerable and acceptable among non-dependent methamphetamine-using and binge-drinking MSM.

Condition or disease Intervention/treatment Phase
Methamphetamine Alcohol Drug: Intermittent Oral Naltrexone Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Study Start Date : May 2013
Actual Primary Completion Date : October 2014
Actual Study Completion Date : November 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Methamphetamine

Arm Intervention/treatment
Active Comparator: Naltrexone
Intermittent oral naltrexone to be taken on an as-needed basis for 8 weeks.
Drug: Intermittent Oral Naltrexone
Placebo Comparator: Placebo
Intermittent oral placebo to be taken on an as-needed basis for 8 weeks
Drug: Placebo

Primary Outcome Measures :
  1. Feasibility of Retaining Participants in Trial [ Time Frame: proportions eligible and enrolled assessed on ongoing basis throughout the study, proportion of visits completed assessed bi-weekly for each participant; overall retention assessed over 2 month follow-up for each participant ]
    Proportion of persons retained by study arm.

  2. Acceptability to Taking Medication [ Time Frame: 2 month follow-up ]
    Mean number of pills taken weekly, as determined by recorded openings from an electronic monitoring device for study medication pill dispensers

  3. Tolerability to Study Drug, as Measured by Adverse Events [ Time Frame: 2 months ]
    Frequency of Adverse Events, by arm

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. male gender or transgender male-to-female
  2. self-reported anal sex with men in the prior six months while under the influence of meth and/or alcohol
  3. self-reported meth use at least bi-weekly in the prior three months
  4. at least weekly binge drinking (five or more drinks on a single drinking session) in the prior three months

4) interested in reducing meth use and/or binge drinking 5) HIV-negative by rapid test or medical record of HIV infection 6) no current acute illnesses requiring prolonged medical care 7) no chronic illnesses that are likely to progress clinically during trial participation 8) able and willing to provide informed consent and adhere to visit schedule 9) age 18-70 years 10) baseline complete blood count (CBC), total protein, albumin, glucose, alkaline phosphatase, creatinine, blood urea nitrogen (BUN), and electrolytes without clinically significant abnormalities as determined by study clinician in conjunction with symptoms, physical exam, and medical history

Exclusion Criteria:

  1. any psychiatric (e.g., depression with suicidal ideation) or medical condition that would preclude safe participation in the protocol
  2. known allergy or previous adverse reaction to naltrexone
  3. current use of or dependence on any opioids or a known medical condition which currently requires or may likely require opioid analgesics
  4. opioid-positive urine test at enrollment
  5. current cluster of differentiation 4 (CD4) count < 200 cells/mm3
  6. moderate or severe liver disease (aspartate aminotransferase, alanine aminotransferase, or total bilirubin > 3 times upper limit of normal)
  7. impaired renal function (creatinine clearance < 60 ml/min)
  8. currently participating in another research study
  9. meth or alcohol dependence as determined by Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (SCID) criteria
  10. any condition that, in the principal investigator and/or study clinician's judgment interferes with safe participation or adherence to study procedures.
  11. unwillingness to provide minimum locator for information
  12. not having a cellular phone that can send or receive a text message
  13. plans to leave the Bay Area during study follow-up
  14. not comfortable speaking and reading English, enough to participate in a program in English

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01723384

Layout table for location information
United States, California
San Francisco Department of Public Health, Substance Use Research Unit
San Francisco, California, United States, 94102
Sponsors and Collaborators
University of California, San Francisco
National Institute on Drug Abuse (NIDA)
Layout table for investigator information
Principal Investigator: Glenn-Milo Santos, PhD University of California, San Francisco
Study Director: Jason Euren, MA San Francisco Department of Public Health
Layout table for additonal information
Responsible Party: Glenn-Milo Santos, Assistant Professor, University of California, San Francisco Identifier: NCT01723384    
Other Study ID Numbers: 12-09809
R36DA035109-01 ( U.S. NIH Grant/Contract )
First Posted: November 7, 2012    Key Record Dates
Results First Posted: February 12, 2019
Last Update Posted: April 23, 2019
Last Verified: April 2019
Keywords provided by Glenn-Milo Santos, University of California, San Francisco:
sexual behavior
Additional relevant MeSH terms:
Layout table for MeSH terms
Alcohol Deterrents
Narcotic Antagonists
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents